Rising GLP-1 prices push U.S. patients toward risky unregulated alternatives

Despite recent improvements, many Americans still cannot afford GLP-1 drugs, with insurers frequently denying coverage for obesity treatment and pricing them at $1,000 to $1,500 per month. As a result, patients such as Robin Washington seek cheaper routes, including compounded versions obtained through telemedicine and a gray market where individuals like Elizabeth Zibilich mix imported peptide powder at home. While the FDA cautions that these unapproved products could pose health risks, users report significant cost savings—sometimes as low as $100 a month—and sustained weight loss.

Insurance carve-outs have risen, with employer coverage for obesity dropping 17 percent in a year, and Medicaid in some states limiting reimbursement to diabetes only. A Medicare pilot program briefly offered Washington GLP-1s for $50 a month, but the benefit is set to end next year, leaving many uncertain about future access.